CORONA Remedies buys 7 brands from Bayer pharma division in India

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-07-17 09:22 GMT   |   Update On 2025-07-17 09:22 GMT
Advertisement

Ahmedabad: CORONA Remedies has announced the acquisition of seven brands from the pharmaceutical division of Bayer in India.

Effective July 16, 2025, the acquisition encompasses several brands within the cardiology segment (NOKLOT) and the women’s healthcare portfolio (FOSTINE, LUPROFACT, MENODAC, OVIDAC, SPYE, and VAGESTON) for the Indian market. This move strengthens CORONA Remedies position in both the cardiology and women's healthcare segments. 

Integrating these acquired brands into its portfolio marks CORONA Remedies entry into the Anti-Platelet Market, which is valued at INR 1507 Cr with an 8% growth rate.

As per the release, the company aims to strengthen CORONA Remedies portfolio in women's healthcare by enhancing its presence in the Gonadotrophin & Progesterone Hormone Market, which stands at INR 1862 Cr as per MAT June’25. This portfolio is primarily utilized for infertility treatment and pregnancy management.

Advertisement

"CORONA Remedies sales & marketing team and extensive distribution network will work to ensure that this newly acquired portfolio reaches patients across metro, semi-metro, urban, semi-urban, and rural areas," the company stated.

The acquisition of these brands is expected to enhance CORONA Remedies market presence and expand its portfolio. GCV Life acted as the advisor for this transaction.

Read also: Simultaneous treatment start with Finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes: Bayer

CORONA Remedies Limited, founded in 2004, is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing & marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.

Read also: Bayer begins Phase I study targeting GPC3 with alpha radiopharmaceutical in advanced hepatocellular carcinoma patients

CORONA manufactures products for healthcare solutions as per international quality standards in its WHO-GMP/EU GMP-certified plant. CORONA has 2 DSIR-approved R&D centres with 80+ scientist teams working on new formulation development. 
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News